A New Front in the Fight Against Cancer: Cellular Senescence and Its Mysterious Role
In this article
Every new insight in the fight against cancer brings hope. Alongside conventional treatments, ongoing research into cancer's complex biology sheds light on different aspects of the disease, opening doors to new strategies. One process attracting considerable scientific interest is a natural phenomenon in our bodies: “cellular aging” , scientifically known as “cellular senescence”. Strong evidence suggests it has a paradoxical and potentially groundbreaking role in cancer treatment.
In this article, we draw on a recent review published on 14 July 2025 in Cancer Cell : "Senescence in Cancer" . Using insights from this review, we will examine senescence's mysterious, multifaceted role in cancer, its complex relationships with the tumor microenvironment, and future treatment approaches.
Cellular Senescence: A Natural Defense Mechanism or a Dual Role?
- Senescence, developed by the body to prevent uncontrolled proliferation of damaged or stressed cells, is a natural defense mechanism.
- First observed by Hayflick and Moorhead in 1961, it has since been recognized both as an important tumor-suppressing mechanism and as a hallmark of aging .
- Senescent cells (SnCs)stop dividing but do not die, unlike cells undergoing programmed cell death (apoptosis).
- Instead, they remain metabolically active and substantially influence their surroundings, particularly the tumor microenvironment (TME) .
- In cancer, senescence plays a paradoxical dual role:
- On the one hand, by arresting the growth of potentially malignant cells, it can prevent tumor development.
- On the other, through a complex secretory profile called the Senescence-Associated Secretory Phenotype (SASP) , it can facilitate tumor progression.
📊 Cancer Cells' “Aging” States: Hallmarks of Senescence
Senescent tumor cells differ fundamentally from quiescent tumor cells that are not actively proliferating but are reversibly “dormant.” Senescent cells generally resist reentering the cell cycle. Senescence is now viewed as a broader concept defined not only by permanent growth arrest but also by biochemical, structural, and functional features :
- Persistent DNA Damage Signaling: Ongoing DNA damage caused by oncogenic or oxidative stress.
- Chromatin Remodeling: Heterochromatinization of proliferative genes.
- Metabolic Changes: Mitochondrial dysfunction and metabolic reprogramming.
- Apoptosis Resistance: Increased resistance to cell death.
- Senescence-Associated Secretory Phenotype (SASP): The complex secretory activity of senescent tumor cells.
SASP: The Conductor of the Tumor Microenvironment (SASPom)
- SASPis one of the defining features of senescent cells and profoundly affects the tumor microenvironment (TME).
- The SASP secretory profile includes not only cytokines and interleukins but also extracellular vesicles, noncoding RNAs, bioactive lipids, and other mediators, forming a broad “SASPom” repertoire .
- These factors reinforce senescence through both autocrine (self-reinforcing) and paracrine (affecting neighboring cells) pathways.
- SASP can modulate immune surveillance, promote tissue remodeling, and affect tumor progression or suppression depending on context .
⚠️ Factors Triggering Cellular Senescence in Cancer
- Oncogene-Induced Senescence (OIS): Abnormal activation of oncogenes such as RAS.
- Loss of Tumor Suppressor Genes (TSGs): Loss of function of genes such as PTEN and Rb.
- Therapy-Induced Senescence (TIS): Many anticancer treatments, including chemotherapy, radiotherapy, targeted therapies, and immunotherapy.
- Targeting Telomerase and Epigenetic Pathways: Telomerase inhibitors and epigenetic modulators.
- Cell-Cycle Inhibition: CDK4/6 inhibitors (such as palbociclib, abemaciclib, ribociclib).
The Dilemma of Senescence in Cancer: Suppressing Tumors or Promoting Progression?
Studies in 2005 showed that OIS acts as a tumor-suppressive barrier against uncontrolled cell proliferation. However, senescence was also shown to contribute to tumor progression. This dual role depends on complex interactions between cellular and microenvironmental factors.
| Role | Effects on Cancer | Mechanism / Example |
|---|---|---|
| Tumor-Suppressing Effect |
|
|
| Tumor-Promoting Effect |
|
|
Senescence in the Tumor Microenvironment: A Cancer Atmosphere
- Senescence in Stromal Cells (SenCAFs): Cancer-associated fibroblasts (CAFs) can undergo senescence, and their SASP can further worsen tumor growth and metastasis.
- Senescence in Immune Cells (Immunosenescence): Immune system aging generally increases cancer risk. Hypofunctional immune cells, such as exhausted T cells, can facilitate tumor immune escape.
- Senescence in the Vasculature (Endothelial Cells): Senescent endothelial cells disrupt vascular architecture and facilitate metastasis.
Strategies Targeting Cellular Senescence in Cancer Treatment
Cell death alone cannot fully explain the therapeutic effects of anticancer agents; the critical role of senescence as a key antiproliferative mechanism cannot be ignored. Targeting senescence has therefore become a promising strategy in oncology.
| Strategy | Goal | Example Compounds / Treatments |
|---|---|---|
| Pro-Senescence Compounds (Senescence Inducers) | Induce cell-cycle arrest in cancer cells and halt tumor growth. |
|
| Senolytic Compounds (Senescent Cell Killers) | Selectively eliminate senescent cancer cells in tumors to reduce treatment resistance and metastasis. |
|
| Senomorphic Compounds (SASP Modulators) | Reduce the harmful effects of accumulated senescent cells by suppressing or reprogramming SASP while preserving their antitumor functions. |
|
The “One–Two Punch” Approach: Using Senescence Strategically
In cancer treatment, the “one–two punch” approachaims to induce tumor senescence with pro-senescence therapies, then eliminate senescent cells with senolytic treatments.
- This strategy could improve therapeutic effects by reducing metastasis and treatment resistance.
- For example, in prostate cancer, combining adapalene with docetaxel-induced harmful SASP increased antitumor factors, enhanced NK-cell activation, and improved tumor suppression.
Biomarkers and Artificial Intelligence for Precision Medicine
- New Identification Tools: Tools such as the Senescence Identification Tool (SIT), SENCAN, SenMayo, and DeepScence offer potential to identify and characterize senescent cells in vivo and in vitro.
- AI-Assisted Pathology: Can identify senescent cells by recognizing morphological features such as enlarged cell size and chromatin reorganization. AI tools such as SAMPs, Deep-SeSMo, and SenPred offer potential for senescence detection and cancer risk prediction.
- Noninvasive Detection (Liquid Biopsy): Detecting SASP factors in body fluids shows considerable promise as a noninvasive biomarker of senescence.
Conclusion and Future Directions: Another Step Toward a Cancer-Free Future
The biological and genetic context of senescence in cancer determines whether its effects are beneficial or harmful. Personalizing treatment according to tumor genomics will help maximize therapeutic effects on cancer cells while anticipating potential consequences within the tumor microenvironment. To support this personalized approach, monitoring senescence levels through circulating biomarkers could provide clinicians with actionable data to inform treatment decisions.
Research into immune cell senescence also has important implications for immune surveillance, tumor progression, and treatment response.
In the future, artificial intelligence and machine learning technologieswill play critical roles in detecting senescent cells, predicting responses, and monitoring treatment effects. By integrating large-scale, multimodal datasets, AI-based models will provide a more comprehensive, advanced understanding of cellular senescence, driving the transformation of precision medicine .
Sources
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.